Preparation and application of adipose-derived mesenchymal stem cell exosome with SphK1 inhibition function

通过制备具有SphK1抑制功能的脂肪间充质干细胞外泌体,解决了肝纤维化治疗中缺乏有效药物的问题,实现了对肝纤维化的显著改善和肝组织修复,提供了一种优于传统 Treatment options for inhibitors.

CN119040258APending Publication Date: 2024-11-29SHANGHAI SIDEXO BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411290590.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The lack of effective anti-fibrotic drugs in the prior art has led to liver transplantation after cirrhosis becoming the only treatment method, but the donor of the liver is insufficient and new therapeutic targets are urgently needed to deal with liver fibrosis.

Method used

By preparing fatty mesenchymal stem cell exosomes with SphK1 inhibitory function, the paracrine pathway exerts anti-inflammatory and tissue repair functions are used to directly inhibit the activation and proliferation of hepatic stellate cells, and remodeling hepatic glutamine synthetase Mediated ammonia metabolism maintains the body's ammonia homeostasis and increases the antioxidant ability of liver tissue.

Benefits of technology

Significantly improve the liver fibrosis phenotype in mice, inhibit the activation and proliferation of liver stellate cells, reduce collagen deposition, improve the antioxidant capacity of liver tissue, and provide a natural SphK1 inhibitor, which is better than the treatment of traditional chemical synthesis inhibitors. Effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005044462460000011
    Figure HDA0005044462460000011
  • Figure HDA0005044462460000012
    Figure HDA0005044462460000012
  • Figure HDA0005044462460000021
    Figure HDA0005044462460000021
Patent Text Reader

Abstract

The invention relates to preparation and application of an adipose-derived mesenchymal stem cell exosome with an SphK1 inhibition function, and belongs to the technical field of biology. Through a specific preparation method, the adipose-derived mesenchymal stem cell exosome is explored and verified to be a biological product capable of inhibiting liver fibrosis key target gene Sphk1. Compared with other chemically synthesized Sphk1 inhibitors, due to the fact that the Sphk1 inhibitors are derived from ADSC mother cells, the Sphk1 inhibitors not only have biological functions similar to ADSC, such as tissue repair and immune microenvironment regulation, but also have the effect of inhibiting Sphk1 expression, and can be applied to development and application of new drugs for subsequent hepatic fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to the preparation and application of adipose mesenchymal stem cell exosomes with SphK1 inhibitory function, and belongs to the field of biotechnology. Background Art

[0002] Fibrosis caused by viral or metabolic chronic liver disease is a major challenge to global health. Chronic liver disease causes approximately 2 million deaths worldwide each year. Fibrosis is closely related to the development of liver disease and the risk of liver cancer. The resulting cirrhosis has become the 11th most common cause of death in the world. Liver fibrosis is a wound healing response that can be caused by a variety of chronic liver injuries, such as drinking, non-alcoholic fatty liver disease, viral hepatitis (hepatitis B and hepatitis C), autoimmune diseases, non-alcoholic fatty liver disease and cholestatic liver disease. Hepatocytes, activated hepatic stellate cells, endothelial cells and immune cells, Kupffer cells and macrophages, jointly participate in the establishment and reversal of liver fibrosis. However, the degree of natural reversal is limited and life-threatening complications cannot be avoided, especially when the liver develops advanced fibrosis. So far, no effective anti-fibrotic drugs have been approved. If cirrhosis occurs, liver transplantation is the only way to cure it. However, the number of donor livers is insufficient, and there is an urgent need to develop effective anti-fibrotic drugs. Therefore, understanding liver fibrosis may provide new therapeutic targets for the treatment of liver fibrosis.

[0003] Sphingosine-1-phosphate (S1P) is a pleiotropic lipid mediator that acts on the cell surface or through G protein-coupled S1P receptors at intracellular target sites. S1P can be converted from sphingosine to two sphingosine kinase isoforms (SphK1 and SphK2). S1P is currently considered an important regulator of renal, pulmonary, skin fibrosis and heart, and has strong cellular chemotaxis among chemokines and inflammatory mediators. Recent studies have reported that S1P / SphK1 / S1PR signaling is involved in liver fibrosis and injury. SphK1 inhibitors can alleviate liver fibrosis in mice to a certain extent, and targeting SphK1 may also be a new and effective therapeutic strategy for the treatment of liver fibrosis.

[0004] Compared with other stem cells, adipose-derived stem cells (ADSCs) are easy to obtain, have rapid in vitro expansion and are easier to obtain, and play a more important role in injury repair and protection against various diseases. Therefore, the development and preparation of new natural biological vesicles based on ADSCs exosomes with SphK1 inhibitory function and their application in the treatment of liver fibrosis have certain prospects. Summary of the invention

[0005] In response to the above problems, the present application provides adipose-derived mesenchymal stem cell exosomes with SphK1 inhibitory function, which can exert anti-inflammatory and tissue repair functions through paracrine pathways, significantly improve the phenotype of liver fibrosis in mice, and at the same time, ADS C-EXO intervention can directly inhibit the activation and proliferation of HSC; and through this, reshape the glutamine and ammonia metabolism mediated by hepatocyte glutamine synthetase, maintain the body's ammonia homeostasis, increase the antioxidant capacity of liver tissue, and play a role in improving the liver microenvironment.

[0006] A method for preparing adipose-derived mesenchymal stem cell exosomes with SphK1 inhibition function comprises the following steps:

[0007] Step 1, culturing adipose-derived mesenchymal stem cells;

[0008] Step 2, using DMEM-F12 medium containing 10% exosome-free serum and 10 ng / ml bFGF to culture adipose-derived stem cells. After 24 hours, the cell confluence reaches 85-95%, and the supernatant is collected. The supernatant cells are used as adipose-derived mesenchymal stem cells of generation P3-P6, and the supernatant is collected;

[0009] Step 3, centrifugation to remove cells, apoptotic bodies or cell debris;

[0010] Step 4, ultracentrifuging the supernatant and incubating at 120,000 g for 70 minutes;

[0011] Step 5: discard all the supernatant and resuspend in 4°C pre-cooled PBS to obtain mesenchymal stem cell exosomes with SphK1 inhibitory function.

[0012] In one embodiment, the method for culturing adipose-derived mesenchymal stem cells in step 1 is as follows: washing adipose tissue with phosphate buffer solution, and digesting adipose tissue fragments with 0.1% collagenase I for 45 minutes; adding an equal volume of complete culture medium, centrifuging at 1000 rpm for 10 minutes; resuspending with PBS and filtering, and purifying with 1×10 6 Cells were seeded at a density of 1:5 / ml in complete medium containing 10 ng / ml b FGF; when the adherent cells approached 80%-90% confluence, the cells were passaged at a density of 1:5.

[0013] In one embodiment, step 3 specifically comprises: pre-centrifuging the cell supernatant collected in step 2 at 500 g for 10 minutes, then centrifuging at 2000 g for 20 minutes to remove cells or apoptotic bodies; and then centrifuging at 10000 g for 60 minutes to remove cell debris.

[0014] In one embodiment, the complete culture medium formula is DMEM-F12 culture medium, 10% FBS, 1% penicillin-streptomycin.

[0015] In one embodiment, the preparation method is to wash the adipose tissue with phosphate buffered saline (PBS) and then 3 Adipose tissue fragments were digested with 0.1% collagenase I for 45 min; an equal volume of complete medium was added and centrifuged at 1000 rpm for 10 min; resuspended in PBS and filtered through a 40 μm cell strainer at 1 × 10 6 The cells were seeded at a density of 1:1 / ml in complete medium containing 10 ng / ml bFGF; when the adherent cells approached 80%-90% confluence, the cells were passaged at a ratio of 1:5;

[0016] ADSC cells were cultured in DMEM-F12 medium containing 10% exosome-free serum and 10 ng / ml bFGF, and the supernatant was collected after 24 h;

[0017] The collected cell supernatant was pre-centrifuged at 500 g for 10 min, followed by centrifugation at 2000 g for 20 min to remove cells or apoptotic bodies, and then centrifuged at 10000 g for 60 min to remove cell debris;

[0018] All supernatants were transferred to ultracentrifuge tubes and subjected to ultracentrifugation at 120,000 g for 70 min to isolate exosomes;

[0019] Afterwards, carefully discard all the supernatant and resuspend the exosomes in 100-150 μl pre-cooled PBS per tube; all centrifugation procedures were performed at 4°C, and the exosomes obtained could be stored at -80°C or used immediately.

[0020] The second object of the present invention is to provide a mesenchymal stem cell exosome having SphK1 inhibitory function prepared by the above method.

[0021] The third object of the present invention is to provide a pharmaceutical composition, comprising adipose-derived mesenchymal stem cell exosomes having SphK1 inhibitory function prepared by any of the above methods and an optional pharmaceutically acceptable carrier.

[0022] The fourth object of the present invention is to provide the use of adipose-derived mesenchymal stem cell exosomes having SphK1 inhibitory function prepared by any of the above methods in the treatment of liver fibrosis.

[0023] Beneficial Effects

[0024] The adipose stem cell exosomes in this patent are a biological derivative that can be secreted by adipose stem cells. We analyze, extract and purify them through a specific process, discover and verify that they are a biological product that can inhibit the key target gene Sphk1 of liver fibrosis. Compared with other chemically synthesized Sphk1 inhibitors, since it is derived from ADSC mother cells, it has both similar biological functions of tissue repair as AD SC and the function of inhibiting Sphk1 expression, and can be used in the subsequent development and application of new drugs for liver fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 ADSC-EXO intervention improves gross liver phenotype and inhibits hepatic stellate cell activation

[0026] Figure 2 ADSC-EXO intervention alleviates collagen deposition in liver fibrosis

[0027] Figure 3 ADSC-EXO inhibits abnormal expression of SPHK1 and CCR2 in liver fibrosis (20×)

[0028] Figure 4 Compared with traditional chemical Sphk1 inhibitors, ADSC-EXO has better tissue repair and anti-fibrosis properties Specific implementation plan

[0029] The scheme of the present invention is further described below by combining implementation examples, which are not limitations of the present invention.

[0030] Example 1 Preparation of adipose stem cell exosomes

[0031] Adipose tissue was obtained from healthy liposuction donors, and all donors signed informed consent. The adipose tissue was washed with phosphate buffered saline (PBS) (Gibco, USA) and the adipose tissue (1 mm 3 ) fragments were digested with 0.1% collagenase I (Gibco, USA) for 45 minutes. Then, an equal volume of complete medium [DMEM-F12 medium (Gibco, USA), 10% FBS, 1% penicillin-streptomycin] was added and centrifuged at 1000 rpm for 10 minutes. Resuspended in PBS and filtered with a 40 μm cell strainer, 1×10 6 Cells were seeded at a density of 1:5 / ml in complete medium containing 10 ng / ml bFGF (Stemcell, USA). When adherent cells approached 80%-90% confluency, cells were passaged at a 1:5 ratio.

[0032] In order to obtain the supernatant containing ADSC-EXO, before cell passage, DMEM-F12 medium containing 10% exosome-free serum and 10ng / ml bFGF was used to culture ADSC cells. After 24 hours, the cell confluence reached 85-95%, and the supernatant was collected. The supernatant cells were used for P3-P6 adipose-derived mesenchymal stem cells. The collected cell supernatant was pre-centrifuged at 500g for 10 minutes, followed by centrifugation at 2000g for 20 minutes to remove cells or apoptotic bodies; and then centrifuged at 10000g for 60 minutes to remove cell debris. All supernatants were transferred to ultracentrifuge tubes (Beckman, #355118) and ultracentrifuged, and cultured at 120000g for 70 minutes to separate exosomes. After that, all supernatants were carefully aspirated and the exosomes were resuspended with 100-150μl pre-cooled PBS per tube. All centrifugation procedures were performed at 4 °C, and the obtained exosomes could be stored at -80 °C or used immediately.

[0033] Example 2 Adipose stem cell exosomes inhibit liver fibrosis

[0034] We used DEN / CCL4 to induce liver fibrosis in mice. Figure 1 As shown in A, DEN (20 mg / kg) was injected intraperitoneally once a week for 2 weeks; CCl4 (5 ml / kg) was injected continuously for 4 weeks, 3 times a week, to establish a liver fibrosis model; then exosome intervention was performed in weeks 7-9, and 200ug ADSC-EXO / 25g mice were given through the tail vein twice a week. Liver gross examination showed that the liver edge of the model control group mice was obviously rounded and blunt, and the texture was dense and hard, with an uneven surface and particles ( Figure 1 B). However, in ADSC-EXO-treated mice, the liver tissue had a soft texture, a smoother surface, restored its original elasticity, a loosened capsule, and disappeared liver granules ( Figure 1 B). In addition, we also tested the hepatic stellate cell activation markers and found that ADSC-EXO intervention significantly inhibited the expression of a-SMA and Collagen I ( Figure 1 CD), indicating that it inhibits the activation of hepatic stellate cells and thus alleviates liver fibrosis.

[0035] In addition, we also analyzed the H&E staining and Sirius red staining ( Figure 2 A) The degree of liver fibrosis was evaluated, and the results showed that the inflammatory cell infiltration in the model control group was significantly reduced compared with that in the ADSC-EXO-treated mice. Sirius red staining showed severe collagen deposition in the liver sections of the model control mice, but ADSC-EXO intervention significantly alleviated collagen deposition ( Figure 2A). We tested collagen III and hyaluronic acid (HA) in serum and found that ADSC-EXO can reduce the levels of both in serum ( Figure 2 B). Detection of Collagen-I and Collagen-IV in tissues. Levels of the two collagens in ADSC-EXO liver tissues ( Figure 2 C).

[0036] Through immunofluorescence detection, we found that compared with the model control group, ADSC-EXO intervention could significantly inhibit the abnormally high expression of sphk1 and CCR2 in the liver of liver fibrosis mice, indicating that ADSC-EXO is a natural SphK1 inhibitor.

[0037] Example 3 Comparison with traditional sphk1 inhibitors

[0038] To compare the effects of traditional chemical synthetic inhibitors and ADSC-EXO on liver fibrosis, we used Figure 4 The operation method in A was used to treat liver fibrosis mice by intraperitoneal injection of PF543 (10 mg / kg), and the therapeutic effect was compared between it and ADSC-EXO. Compared with the traditional sphk1 inhibitor PF543, ADSC-EXO had a significant recovery effect on the liver function indicators ALT, AST, and TBIL in serum biochemistry, and neither had a significant regulation on the ALP level in serum ( Figure 4 B), the results show that ADSC-EXO has a better effect on liver function recovery than ordinary Sphk1 chemical synthesis inhibitors. In addition, Western blot analysis of mouse liver tissue showed that both ADSC-EXO and inhibitor intervention reduced the expression levels of Collagen I and α-SMA, and inhibited the expression levels of Sphk1 and CCR2 ( Figure 4 C), indicating that Sphk1 is an important factor in mediating liver fibrosis. HE staining showed that both ADSC-EXO and PF543 interventions could reduce the infiltration of inflammatory cells, and exosomes had more significant improvements in tissue repair and tissue congestion. Sirius red staining showed that compared with PF543, ADSC-EXO also had a stronger ability to reduce collagen deposition in tissues ( Figure 4 D).

[0039] The above results indicate that Sphk1 is an important factor mediating liver fibrosis, and the ADSC-EXO we prepared has the function of inhibiting the expression of Sphk1, thereby mediating the reversal of liver fibrosis.

Claims

1. A method for preparing adipose-derived mesenchymal stem cell exosomes with SphK1 inhibitory function, It is characterized in that The preparation method comprises the following steps: Step 1, culturing adipose-derived mesenchymal stem cells; Step 2, adipose-derived stem cells were cultured in DMEM-F12 medium containing 10% exosome-free serum and 10 ng / ml bFGF. After 24 hours, the cell confluence reached 85-95%, and the supernatant was collected. The supernatant cells were used as P3-P6 adipose-derived mesenchymal stem cells; Step 3, centrifugation to remove cells, apoptotic bodies or cell debris; Step 4, ultracentrifuging the supernatant at 120,000 g for 70 minutes; Step 5: discard all the supernatant and resuspend in 4°C pre-cooled PBS to obtain mesenchymal stem cell exosomes with SphK1 inhibitory function.

2. The method for preparing adipose-derived mesenchymal stem cell exosomes having SphK1 inhibitory function according to claim 1, It is characterized in that The method for culturing adipose stem cells in step 1 is as follows: washing adipose tissue with phosphate buffer solution, and digesting adipose tissue fragments with 0.1% collagenase I for 45 minutes; adding an equal volume of complete culture medium, centrifuging at 1000 rpm for 10 minutes; resuspending with PBS and filtering, and 6 Cells were seeded at a density of 1:5 / ml in complete medium containing 10 ng / ml bFGF; when the adherent cells approached 80%-90% confluence, the cells were passaged at a density of 1:

5.

3. The method for preparing adipose-derived mesenchymal stem cell exosomes having SphK1 inhibitory function according to claim 1, It is characterized in that The step 3 specifically comprises: pre-centrifuging the cell supernatant collected in step 2 at 500 g for 10 minutes, then centrifuging at 2000 g for 20 minutes to remove cells or apoptotic bodies; and then centrifuging at 10000 g for 60 minutes to remove cell debris.

4. The method for preparing adipose-derived mesenchymal stem cell exosomes having SphK1 inhibitory function according to claim 2, It is characterized in that The complete culture medium formula is DMEM-F12 culture medium, 10% FBS, and 1% penicillin-streptomycin.

5. Adipose-derived mesenchymal stem cell exosomes with SphK1 inhibitory function prepared according to the method of any one of claims 1 to 4. 6 . A pharmaceutical composition comprising adipose-derived mesenchymal stem cell exosomes having SphK1 inhibitory function prepared by the method of any one of claims 1 to 4 and an optional pharmaceutically acceptable carrier.

7. Use of adipose-derived mesenchymal stem cell exosomes with SphK1 inhibitory function prepared according to any one of claims 1 to 4 in the treatment of liver fibrosis.

Citation Information

Patent Citations

  • Composition containing adipose stem cell-derived exosomes as active ingredient for preventing or treating liver fibrosis

    CN109963574A

  • Preparation method and application of fat-derived stem cell exosomes

    CN111304164A

  • Composition for improving hepatic fibrosis and preparation method and application thereof

    CN113384598A

Cited By

  • Nerve cell injury repairing composition as well as preparation method and application thereof

    CN120531853A

  • A nerve cell injury repair composition, a preparation method therefor, and use thereof

    CN120531853B

  • Mechanical response type engineered mesenchymal stem cell exosome preparation for treating diseases caused by fibrosis inflammation as well as preparation method and application of mechanical response type engineered mesenchymal stem cell exosome preparation

    CN121197221A